What the FDA labels say about taking them together
Elbasvir/grazoprevir and lopinavir/ritonavir
Lopinavir/ritonavir's FDA label of July 23, 2026 names elbasvir/grazoprevir in its contraindications section; the elbasvir/grazoprevir label PlainMeds reads does not name lopinavir/ritonavir. The lopinavir/ritonavir label: “Hepatitis C direct acting antiviral: elbasvir/grazoprevir ↑ elbasvir/grazoprevir Contraindicated due to increased risk of alanine transaminase (ALT) elevations.”
Check it at the source: the elbasvir/grazoprevir FDA label on DailyMed (effective March 13, 2026, Merck Sharp & Dohme LLC); the lopinavir/ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.).
What does the elbasvir/grazoprevir label say about lopinavir/ritonavir?
Elbasvir/grazoprevir's label (effective March 13, 2026) does not name lopinavir/ritonavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (ZEPATIER), Merck Sharp & Dohme LLC, effective March 13, 2026 (SPL set 164dc02a-9180-426a-b8b5-04ab39d2bbd4), via openFDA; the full label on DailyMed
What does the lopinavir/ritonavir label say about elbasvir/grazoprevir?
Lopinavir/ritonavir label, contraindicationsAlpha 1- Adrenoreceptor Antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anti-gout: colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine GI Motility Agent: cisapride Hepatitis C direct acting antiviral: elbasvir/grazoprevir HMG-CoA Reductase Inhibitors: lovastatin, simvastatin Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide Non-opioid Analgesic (selective blocker of Nav1.8 sodium channels): suzetrigine PDE5 Inhibitor: sildenafil (Revatio ® ) when used for the treatment of pulmonary arterial hypertension Sedative/Hypnotics: triazolam, orally administered midazolam KALETRA is …
Lopinavir/ritonavir label, drug interactionsHepatitis C direct acting antiviral: elbasvir/grazoprevir ↑ elbasvir/grazoprevir Contraindicated due to increased risk of alanine transaminase (ALT) elevations [see Contraindications ( 4 )].
Source: FDA drug label (Kaletra), AbbVie Inc., effective July 23, 2026 (SPL set 8290add3-4449-4e58-6c97-8fe1eec972e3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Elbasvir/grazoprevir | Lopinavir/ritonavir | |
|---|---|---|
| Labeled for | Hepatitis C | HIV |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $4.46 per tablet 200-50 mg tablet |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once